CD38 and neoplasm: The data indicated that both CD38 inhibition and anti‐PD‐1 therapy significantly inhibited tumor growth compared with that in the vehicle + IgG group, with the combination therapy exhibiting the most pronounced therapeutic benefits (Figure 7B,C).